Case Page

 

Case Status:    DISMISSED    
On or around 02/27/2018 (Court's order of dismissal)

Filing Date: February 13, 2018

Juno Therapeutics, Inc. ("Juno") is a biopharmaceutical company focused on developing cell-based cancer immunotherapies.

According to the Complaint, Juno has several collaboration agreements with various third-party companies, including Celgene. On January 28, 2018, Juno and Celgene issued a press release announcing the
Proposed Transaction, in which Celgene will acquire each outstanding share of Juno common stock for $87.00 per share in cash, with a total valuation of approximately $9 billion.

The terms of the Proposed Transaction were memorialized in a January 22, 2018, filing with the Securities and Exchange Commission (“SEC”) on Form 8-K attaching the definitive Agreement and Plan of Merger (the “Merger Agreement”). Thereafter, on January 16, 2018, Juno filed a Solicitation/Recommendation Statement on February 2, 2018 (the “14D-9”) with the Securities and Exchange Commission (the “SEC”) in support of the Proposed Transaction.

The Complaint alleges that Defendants breached their fiduciary duties to the Company’s stockholders by agreeing to the Proposed Transaction which undervalues Juno and is the result of a flawed sales process, and that in violation of sections 14(d), 14(e) and 20(a) of the Securities and Exchange Act of 1934 (the “Exchange Act”), and in violation of their fiduciary duties, Defendants caused to be filed the materially deficient 14D-9 on February 2, 2018 with the United States Securities and Exchange Commission (“SEC”) in an effort to solicit stockholders to tender their Juno shares in favor of the Proposed Transaction.

This case was voluntarily dismissed on February 26, 2018.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: JUNO
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: W.D. Washington
DOCKET #: 18-CV-00229
JUDGE: Hon. John C Coughenour
DATE FILED: 02/13/2018
CLASS PERIOD START: 01/28/2018
CLASS PERIOD END: 02/13/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Breskin Johnson Townsend PLLC
    1111 Third Avenue, Suite 2230, Breskin Johnson Townsend PLLC, WA 98101
    206.652.8660 206.652.8660 ·
  2. Brodsky & Smith, LLC
    Two Bala Plaza, Suite 602, Brodsky & Smith, LLC, PA 19004
    610.667.6200 610.667.6200 ·
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available